Loading...
Symbols:
Loading...
Symbols:
MedImmune Inc. (MEDI)
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on MedImmune Inc. (MEDI)
52 articles
Filter by:
Latest Articles Most commented on articlesMost frequent authors on MEDI
- SA Editors(10)
- Centient Biotech Investor(9)
- Robert Zenilman(5)
- Lon Juricic(4)
- SA Editor Judith Levy(3)
Most popular authors
(tracked in watchlists)
- Bespoke Investment Group(571)
- SA Editor Eli Hoffmann(386)
- Alan Brochstein(131)
- SA Editor Miriam Metzinger(116)
- Bill Gross(54)
Most commented on authors
- BioBlogger (5)
- Alan Brochstein(3)
- Centient Biotech Investor(2)
- Archie MacAllaster(2)
- Felix Zulauf(2)
- Russell 1,000's Best, Worst Performing Stocks Since March 5 Bottom
- MedImmune's Beat Quarter Sends Shares Higher
- AstraZeneca's MedImmune Acquisition Should Receive Regulatory Approval
- Valuing Sepracor Through Astra-Zeneca's MedImmune Goggles
- AstraZeneca To Buy MedImmune: Did They Overpay?
- AstraZeneca to Buy MedImmune for $15.6 Billion
- A Close Reading Of Carl Icahn's Medimmune Press Release
- Running and Gunning Into Earnings Season: Time to Take Profits?
- MedImmune: Icahn No Longer Intends to Nominate Opposing Board
- Friedman Billings Downgrades MedImmune After Strong Performance
- MedImmune Considering Possible Sale
- Icahn's Golden Touch: MedImmune Up 12%
- Biotech Day In Review: MedImmune Puts Itself Up For Sale
-
Jim Cramer's Mad Money Lightning Round Picks, March 15
on Mar 16, 2007
- Generics Hoping to Solve Drug Bottleneck Problem
- Biotech Day In Review: Genentech Loses Cabilly Patent Ruling
- Genentech to Appeal Cabilly Patent Rejection
- Top 25 S&P 500 Stocks By Growth Forecast
- Biotech Day in Review: Shire Buys New River for $2.6 Billion
- Icahn Management: Notable 13F Changes
- Biotech Day in Review: FluMist from MedImmune Outperforms Injected Vaccine
- Biotech Day In Review: Osiris Stem Cells Treatment Has Unexpected Results
- Biotech Stocks Day-In-Review: Amgen Rises On Speculation Over Patent Suit
- Barron's 2007 Analyst Roundtable, Part II
- Top Picks for 2007 from JPMorgan HealthCare Analysts
- Biotech Stocks Day-in-Review: Genentech Beats Estimates
- MedImmune vs. Genentech: Supreme Court Ruling Facilitates Patent Challenges
- Biotech Stocks Review: Seattle Genetics Sells Cancer Drug To Genentech
- FDA Approves New Version of MedImmune Flu Vaccine
- Matrix Asset Advisors Urges Sale of MedImmune
- Vanda's Success Pays For MedImmune Investors
- Chart: Biotech Stocks - Annual Earnings Growth
- Chart: Biotech Stocks - Quarterly Earnings Growth
- Chart: Biotech Stocks - Annual Revenue Growth (Last 12 Months Reported)
- Chart: Biotech Stocks - Quarterly Revenue Growth
- Chart: Biotech Stocks - Change in Cash-On-Hand
-
Chart: Biotech Stocks - Normalized Net Income Per Employee
on Jun 09, 2006
- Chart: Biotech Stocks - Revenue Per Employee
- Chart: Biotech Stocks - Normalized Net Profit Margins
- Chart: Biotech Stocks - SG&A Margin (MRQ)
- Chart: Biotech Stocks - Gross Profit Margins
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »